Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about VIRACTA THERAPEUTICS, INC.
11/11Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporat..
AQ
11/10VIRACTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/10Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/10Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporat..
PU
11/10SUNESIS : Q3 Earnings Snapshot
AQ
11/08Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and O..
AQ
11/05Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 Ameri..
AQ
11/05Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and O..
PU
11/05VIRACTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a ..
AQ
11/05Viracta Therapeutics, Inc. Secures $50 Million Credit Facility from Silicon Valley Bank..
CI
10/06VIRACTA THERAPEUTICS : Multinational trial expands Viracta's clinical-stage pipeline beyon..
PU
10/06VIRACTA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/06Viracta Therapeutics Starts Trial of Nanatinostat in Epstein-Barr Virus-Positive Solid ..
MT
10/06Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) S..
CI
09/20VIRACTA THERAPEUTICS, INC.(NASDAQGS : VIRX) added to S&P Global BMI Index
CI
09/07VIRACTA : Therapeutics to Present at Upcoming Investor Conferences in September
PR
08/23Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
DJ
08/23VIRACTA THERAPEUTICS : Reacquires Exclusive Rights to Combination Therapy Candidate for Ly..
MT
08/23VIRACTA THERAPEUTICS : Reacquires Exclusive Development and Commercialization Rights for i..
PU
08/23VIRACTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a ..
AQ
08/23VIRACTA : Therapeutics Reacquires Exclusive Development and Commercialization Rights for i..
PR
08/17VIRACTA THERAPEUTICS : Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. B..
AQ
08/16VIRACTA THERAPEUTICS : Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. B..
PU
08/16VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disc..
AQ
08/16Viracta Therapeutics, Inc. Announces Board Appointments
CI
08/12VIRACTA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/12VIRACTA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Clinical..
PU
08/12VIRACTA THERAPEUTICS, INC. : Financial Statements and Exhibits, Regulation FD Disclosure (..
AQ
08/12SUNESIS : Q2 Earnings Snapshot
AQ
08/12VIRACTA : Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical..
PR
08/12Viracta Therapeutics, Inc Announces Consolidated Unaudited Earnings Results for the Sec..
CI
07/21VIRACTA THERAPEUTICS : Says FDA Greenlights Phase 1b/2 Trial in EBV+ Solid Tumors
MT
07/21VIRACTA THERAPEUTICS : Announces FDA Clearance of IND Application for Phase 1b/2 Trial in ..
PU
07/21VIRACTA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/21VIRACTA THERAPEUTICS : Announces FDA Clearance of IND Application for Phase 1b/2 Trial in ..
PR
07/07VIRACTA THERAPEUTICS : Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scien..
AQ
07/06VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/29VIRACTA THERAPEUTICS : Announces its Addition to the Russell 2000 Index and other FTSE Rus..
AQ
06/28VIRACTA THERAPEUTICS : Announces its Addition to the Russell 2000« Index and other FTSE Ru..
PR
06/18SUNESIS : Q1 Earnings Snapshot
AQ
06/03VIRACTA THERAPEUTICS : Jefferies Virtual Healthcare Conference Presentation
PU
06/01Viracta Therapeutics Initiates Phase 2 Trial to Evaluate Nanatinostat-Valganciclovir Co..
MT
06/01Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial ..
CI
06/01VIRACTA THERAPEUTICS : Files $200 Million Mixed Shelf
MT
05/28VIRACTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Dir..
AQ
05/28VIRACTA THERAPEUTICS : At-The-Market Agreement (Form 8-K)
PU
05/28Viracta Therapeutics, Inc.'s Subsidiary, Viracta Subsidiary, Inc. and Silicon Valley Ba..
CI
05/28VIRACTA THERAPEUTICS : to Present at the Jefferies Virtual Healthcare Conference
AQ
05/20VIRACTA THERAPEUTICS : Kol
PU
05/19VIRACTA THERAPEUTICS : to Host Key Opinion Leader Webinar
AQ
05/14VIRACTA THERAPEUTICS : Reports First Quarter 2021 Financial Results and Provides Clinical ..
PU
05/13VIRACTA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
05/12VIRACTA THERAPEUTICS, INC. : Financial Statements and Exhibits, Other Events (form 8-K)
AQ
05/12Viracta Therapeutics, Inc. Reports Consolidated Earnings Results for the First Quarter ..
CI
05/03VIRACTA THERAPEUTICS : HC Wainwright Starts Viracta Therapeutics at Buy With $35 Price Tar..
MT
04/26VIRACTA THERAPEUTICS : SVB Leerink Initiates Viracta Therapeutics at Outperform With $18 P..
MT
04/14VIRACTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
04/09VIRACTA THERAPEUTICS : to Present at the 20th Annual Needham Virtual Healthcare Conference
AQ
04/01VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
03/25VIRACTA THERAPEUTICS : Evercore ISI Starts Viracta Therapeutics at Outperform with $45 Pri..
MT
03/23VIRACTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acq..
AQ
03/23VIRACTA THERAPEUTICS : Financial Statements and Exhibits (form 8-K/A)
AQ
03/23VIRACTA THERAPEUTICS : Agrees to Sell Potential Milestones, Royalties on Drug Candidates t..
MT
03/23Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction
CI
03/04VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disc..
AQ
03/04Viracta Therapeutics, Inc. Announces Executive Changes
CI
03/03VIRACTA : Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference
PR
02/25VIRACTA THERAPEUTICS, INC.(NASDAQGS : VIRX) added to NASDAQ Composite Index
CI
02/24Viracta Therapeutics, Inc. Announces Executive Changes
CI
02/16Viracta Therapeutics, Inc. Announces Notice of Allowance for U.S. Patent Application Co..
CI
2020Viracta Therapeutics, Inc. announced that it has received $40 million in funding from a..
CI
2020Viracta Therapeutics, Inc. announced that it expects to receive $40 million in funding
CI
2020Viracta Therapeutics, Inc. Announces Board Changes
CI
2020Viracta Therapeutics, Inc. Announces Appointment of Roger J. Pomerantz, MD to its Board..
CI
2020Viracta Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer
CI
1  2Next
Upcoming event on VIRACTA THERAPEUTICS, INC.